GL1X · GenesisL1 explorer

MolNFT v1 · #102631 · protein

Rat dihydroorotate dehydrogenase bound with DSM338 (N-[3,5-difluoro-4- (TRIFLUOROMETHYL)PHENYL]-5-methyl-2-(TRIFLUOROMETHYL)[1,2, 4]TRIAZOLO[1,5-A]PYRIMIDIN-7-amine)

4ORI · Dihydroorotate dehydrogenase (quinone), mitochondrial: “Rat dihydroorotate dehydrogenase bound with DSM338 (N-[3,5-difluoro-4…”. X-ray diffraction, 3 ligands (FMN, ORO, 2V6), 4 pockets (best druggability 0.84). MolNFT v1 #102631 on…

PDB
4ORI
Type
protein
Length
355 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Dihydroorotate dehydrogenase (quinone), mitochondrial
EC
1.3.5.2
UniProt
Q63707
Ligands
FMN, ORO, 2V6
Pockets
4 · best druggability 0.84

Structure

x-ray diffraction · 1 distinct chain · 45% helix, 17% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ADihydroorotate dehydrogenase (quinone), mitochondrial (EC 1.3.5.2)protein35545% helix, 17% strandQ63707

Ligands and binding sites

  • FMN · Flavin mononucleotide · ligand · chains A
  • ORO · Orotic acid · ligand · chains A
  • 2V6 · N-[3,5-difluoro-4-(trifluoromethyl)phenyl]-5-methyl-2-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine · ligand · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
15410.840.9073FMN, ORO, 2V6
21140.480.7920empty
3900.380.7617empty
4660.340.7716empty

Compared structures

  • 4ORI · Rat dihydroorotate dehydrogenase bound with DSM338… · the same entry in another collection · chain A against A, TM-score 1.00
  • Q63707 · AlphaFold monomer V2.0 prediction for dihydroorotate dehydrogenase (quinone)… · a predicted model of the same protein · chain A against A, TM-score 0.99

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.